Newsfeeds - Spark Newswire

1 minute read

UPDATE: Raymond James Upgrades ChemoCentryx from Outperform to Strong Buy, Raises Price Target from $62 to $107

Today, 6:36 PM

Raymond James analyst Steven Seedhouse upgrades ChemoCentryx (NASDAQ:CCXI) from Outperform to Strong Buy and raises the price target from $62 to $107.

CCXI

2 minute read

12 Health Care Stocks Moving In Friday’s Intraday Session

By Benzinga Insights

Today, 6:36 PM

AGRX

2 minute read

Mid-Day Market Update: Crude Oil Rises 2%; Allogene Therapeutics Shares Plunge

By Lisa Levin

Today, 6:36 PM

Midway through trading Friday, the Dow traded down 0.06% to 34,734.52 while the NASDAQ fell 0.25% to 14,617.60. The S&P also fell, dropping 0.08% to 4,396.09.

AEHR

1 minute read

EXCLUSIVE: ChemoCentryx Plans To Start Phase 3 Avacopan Trial In Chronic Skin Disorder In 2022

By Vandana Singh

Today, 6:36 PM

After a tight advisory committee vote back in May tilted just slightly in favor of approving ChemoCentryx Inc's (NASDAQ: CCXI) avacopan, the FDA has cleared the drug for an autoimmune disorder that destroys the small blood vessels.

CCXI

2 minute read

28 Stocks Moving In Friday’s Mid-Day Session

By Lisa Levin

Today, 6:36 PM

Gainers

AEHR

2 minute read

Mid-Morning Market Update: Markets Edge Higher; US Economy Adds 194,000 Jobs In September

By Lisa Levin

Today, 6:36 PM

Following the market opening Friday, the Dow traded up 0.12% to 34,796.95 while the NASDAQ rose 0.09% to 14,667.44. The S&P also rose, gaining 0.16% to 4,406.93.

ALLO

1 minute read

12 Health Care Stocks Moving In Friday’s Pre-Market Session

By Benzinga Insights

Today, 6:36 PM

ACCD

1 minute read

Why Did ChemoCentryx Shares Soar 70% On Friday Premarket?

By Vandana Singh

Today, 6:36 PM

The FDA has approved ChemoCentryx Inc’s (NASDAQ:CCXI) Tavneos (avacopan) as an adjunctive treatment for anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis or…

CCXI